In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 5, 2017, Pages 1373-1385

  Livermore, David M ^a,b   Mushtaq, Shazad ^a   Warner, Marina ^a   Vickers, Anna ^a   Woodford, Neil ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE AMPC; CEFEPIME; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PIPERACILLIN; TAZOBACTAM; ZIDEBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CYCLOOCTANE DERIVATIVE; PIPERIDINE DERIVATIVE;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CITROBACTER FREUNDII; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; SERRATIA; STENOTROPHOMONAS MALTOPHILIA; CITROBACTER; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; KLEBSIELLA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; CITROBACTER; CYCLOOCTANES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; PIPERIDINES;

EID: 85020135744     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw593     Document Type: Article

References (20)

1. Shlaes DM. New b-lactam-β-lactamase inhibitor combinations in clinical development. AnnNYAcadSci 2013; 1277: 105-14
2. Zasowski EJ, Rybak JM, RybakMJ. The b-lactams strike back: ceftazidimeavibactam. Pharmacotherapy 2015; 35: 755-70
3. Lucasti C, Vasile L, SandescDet al. Phase 2, dose-ranging study of relebactam with imipenem/cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 2016; 60: 6234-43
4. Morinaka A, Tsutsumi Y, Yamada M et al. OP0595, a new diazabicyclooctane: mode of action as a serine b-lactamase inhibitor, antibiotic and b-lactam 'enhancer'. J Antimicrob Chemother 2015; 70: 2779-86
5. Livermore DM, Mushtaq S, Warner M et al. Activity of OP0595/b-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing b-lactamases. J Antimicrob Chemother 2015; 70: 3032-41
6. Neu HC. Mecillinam-an amidino penicillin which acts synergistically with other b-lactam compounds. J Antimicrob Chemother 1977; 3 Suppl B: 43-52
7. Livermore DM, Warner M, Mushtaq S et al. Interactions of OP0595, a novel triple-action diazabicyclooctane, with b-lactams against OP0595-resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother 2015; 60: 554-60
8. Turton JF, Woodford N, Glover J et al. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. JClinMicrobiol 2006; 44: 2974-6
9. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011; 66: 48-53
10. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012
11. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with b-lactams against Gram-negative bacteria, including OXA-48 b-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39: 86-9
12. Moya B, Barcelo I, Bhagwat S et al. WCK 5107 & WCK 5153: bicycloacyl hydrazides PBP2 inhibitors showing potent b-lactam enhancer activity against Acinetobacter baumannii, including multi-drug-resistant (MDR) carbapenemase-producing clinical strains. In: Abstracts of the Twenty-sixth European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands, 2016. Abstract PLB42. European Society of ClinicalMicrobiology and Infectious Diseases, Basel, Switzerland
13. DoumithM, Mushtaq S, Livermore DM, Woodford N. Newinsights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080. J Antimicrob Chemother 2016; 71: 2810-4
14. Thulin E, SundqvistM, Andersson DI. Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selectedmutants of Escherichia coli. Antimicrob Agents Chemother 2015; 59: 1718-27
15. Barbour AG, Mayer LW, Spratt BG. Mecillinam resistance in Escherichia coli: dissociation of growth inhibition and morphologic change. J Infect Dis 1981; 143: 114-21
16. Livermore DM, Mushtaq S, Barker K et al. Characterization of b-lactamase and porin mutants of Enterobacteriaceae selected with ceftarolineavibactam(NXL104). J Antimicrob Chemother 2012; 67: 1354-8
17. Bethel CR, Papp-Wallace KM, Barnes MD et al. Novel bridged diazabicyclooctanes (DBOS) are effective inhibitors of representative class A, C, and D b-lactamases expressed bymultidrug-resistant (MDR) pathogens. Presented in: Session 373 atMicrobe 2016, Boston, MA, USA. http://www. abstractsonline. com/pp8/#!/4060/presentation/17626. American Society for Microbiology, Washington DC, USA
18. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinasemediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22
19. HuRM, Chiang KH, Chang YC, Yang TC. Characterization of the charge variants of L2 b-lactamase in Stenotrophomonas maltophilia. J Med Microbiol 2009; 58: 318-21
20. Camargo JF, Simkins J, Beduschi T et al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2015; 59: 5903-8